Trial Profile
Research for biomarkers to predict the effectiveness of denosumab in metastatic bone tumors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Feb 2020
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Bone disorders; Bone metastases
- Focus Biomarker; Pharmacodynamics
- 19 Feb 2020 Status changed from active, no longer recruiting to completed.
- 12 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 01 Dec 2015 New trial record